The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 07, 2023
Filed:
Nov. 24, 2020
Applicants:
Dana-farber Cancer Institute, Inc., Boston, MA (US);
The General Hospital Corporation, Boston, MA (US);
Inventors:
Kai W. Wucherpfennig, Brookline, MA (US);
Glenn Dranoff, Sudbury, MA (US);
Penghui Zhou, Quincy, MA (US);
Donald Shaffer, Boston, MA (US);
Nir Hacohen, Brookline, MA (US);
Harvey I. Cantor, Wellesley, MA (US);
Diana Alvarez Arias, Midland, MI (US);
Assignees:
DANA FARBER CANCER INSTITUTE, INC., Boston, MA (US);
THE GENERAL HOSPITAL CORPORATION, Boston, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 35/17 (2015.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01); A61K 39/00 (2006.01); C07K 16/32 (2006.01); C12Q 1/6886 (2018.01);
U.S. Cl.
CPC ...
C12N 15/1137 (2013.01); A61K 35/17 (2013.01); A61K 39/0011 (2013.01); A61K 39/001195 (2018.08); C07K 14/7051 (2013.01); C07K 16/32 (2013.01); C12N 5/0638 (2013.01); C12N 15/113 (2013.01); C12Q 1/6886 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/585 (2013.01); C07K 2317/24 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2319/33 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12N 2320/31 (2013.01); C12N 2320/32 (2013.01); C12Q 2600/178 (2013.01);
Abstract
The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.